
==== Front
Acta Biochim Biophys Sin (Shanghai)
Acta Biochim Biophys Sin (Shanghai)
ABBS
Acta Biochimica et Biophysica Sinica
1672-9145
1745-7270
Science Press

38915288
10.3724/abbs.2024112
Research Article
Importance of PTM of FLT3 in acute myeloid leukemia
Importance of PTM of FLT3 in acute myeloid leukemia
Liu Jianwei *
Gu Jianguo *
Division of Regulatory Glycobiology Institute of Molecular Biomembrane and Glycobiology Tohoku Medical and Pharmaceutical University 4-4-1 Komatsushima Aoba-ku Sendai Miyagi 981-8558 Japan
Correspondence address. Tel: +81-22-7270215; (J.L.) / E-mail: (J.G.)2425406420@qq.comjgu@tohoku-mpu.ac.jp
24 6 2024
25 8 2024
56 8 11991207
27 4 2024
14 6 2024
© The Author(s) 2021.
2024
The Author(s)
0
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed in hematopoietic cells. Internal-tandem duplication domain (ITD) mutation and tyrosine kinase domain (TKD) mutation are the two most common mutations in acute myeloid leukemia (AML). Post-translational modifications (PTMs) of FLT3, such as glycosylation and ubiquitination, have been shown to impact various aspects of the protein in both wild-type (WT) and mutant forms of FLT3. In this review, we describe how the glycosylation status of FLT3 affects its subcellular localization, which significantly impacts the activation of downstream signaling, and the impact of specific ubiquitination on FLT3 function and stability, which may be associated with disease progression. Moreover, potential novel therapeutic strategies involving a combination of FLT3 tyrosine kinase inhibitors and drugs targeting glycosylation or ubiquitination are discussed.

FLT3
glycosylation
ubiquitination
cellular signaling
AML
This work was partially supported by Grants-in-Aid for Scientific Research23H02440 23K27133 to J.G. a Grant-in-Aid for Challenging Exploratory Research22K19443 to J.G. This work was partially supported by Grants-in-Aid for Scientific Research (23H02440 and 23K27133 to J.G.) and a Grant-in-Aid for Challenging Exploratory Research (22K19443 to J.G.) from the Japan Society for the Promotion of Science (JSPS).CitationJ Liu, J Gu. Importance of PTM of FLT3 in acute myeloid leukemia. Acta Biochim Biophys Sin, 2024, Vol.: fpage–lpage, https://doi.org/10.3724/abbs.2024112
Crossmark2024/6/19 14:27:18
AuthorMarkJ Liu
AuthorMarkCiteJ Liu, J Gu.
article-titleImportance of PTM of FLT3 in acute myeloid leukemia
==== Body
pmcIntroduction

Acute myeloid leukemia (AML) is a hematological malignancy originated from hematopoietic stem cells [1]. While relatively uncommon, comprising only 1% of all cancer diagnoses, AML is the predominant form of leukemia in the adult population [2]. The estimated 5-year overall survival rate is 30%, exhibiting significant variation across age groups, reaching 50% in younger patients and decreasing to below 10% in patients older than 60 years [3]. Several risk factors, including myelodysplastic syndrome (MDS), myeloproliferative disease, environmental exposures, and genetic predispositions, play a role in the pathogenesis of AML [2]. It is characterized by the clonal expansion of immature myeloid blast cells in the peripheral blood and bone marrow, leading to ineffective erythropoiesis and bone marrow failure [4]. With recent advancements in management guidelines, the overall cure rate has improved in younger patients. Although therapeutic regimens have advanced, the prognosis for the elderly population remains poor [5]. Mutations in genes involved in hematopoiesis are a significant feature of AML. Among them, FMS-like tyrosine kinase 3 (FLT3) is the most common mutation in AML [6]. The FLT3 protein belongs to the type III receptor tyrosine kinase (RTK) family, which is exclusively expressed in normal bone marrow stem/progenitor cells [7]. FLT3 is activated by binding of the FLT3 ligand (FL). Following activation, homodimers are assembled in the plasma membrane, resulting in receptor autophosphorylation. Activated FLT3 phosphorylates various effector molecules involved in the proliferation, differentiation, and apoptosis of hematopoietic cells. Approximately 30% of AML patients harbor constitutively activating mutations in the FLT3 gene, mostly internal tandem duplications (ITDs), which represent the insertion of nucleotide sequences of different lengths and at different sites [8]. The other predominant point mutation is the tyrosine kinase domain (TKD) mutation [9]. Papaemmanuil et al. [6] conducted a comprehensive study involving 1540 patients diagnosed with AML and reported the presence of FLT3 mutations in more than 500 patients. Christian et al. [10] performed a study involving 1485 patients diagnosed with AML and reported that the frequency of FLT3-ITD mutations was 312 of 1485 (21%). Bacher et al. [11] analyzed the mutational status and clinical significance of FLT3-TKD. They investigated 3082 patients with AML and observed FLT3-TKD mutations in 147 patients (4.8%). Furthermore, Ozeki et al. [12] reported that even in patients with wild-type (WT) FLT3, a discernible increase in overall survival was found in patients with high FLT3 expression (5 of 86 patients without FLT3-ITD mutations).

Among the various biological macromolecules, proteins display the most incredible diversity in function and structure. The gene-encoded primary polypeptide sequences of proteins primarily determine the structural and functional diversity of the cell proteome. However, this fundamental framework is significantly enhanced by alternative splicing of transcripts and a diverse range of post-translational modifications (PTMs). PTMs involve the covalent attachment of specific chemical groups to amino acid side chains through enzymatic or non-enzymatic processes [13]. PTMs have the potential to impact various facets of protein function, such as activity, subcellular localization, protein stability, intracellular signaling pathways, gene expression regulation, and cell-matrix interactions [14]. This review primarily focuses on PTMs of FLT3 in acute myeloid leukemia.

Structure and Function of FLT3-WT and Its Mutants

There are two known forms of the FLT3 receptor according to western blot analysis. One is a mature form at approximately 150 kDa, which is thought to be complex glycosylated and expressed on the cell surface to activate mitogen-activated protein kinase (MAPK) signaling pathways. The other is an immature form at approximately 130 kDa, which represents an oligomannose form [15]. FLT3 has a protein structure similar to that of other type III receptor tyrosine kinases, featuring a kinase domain in the intracellular domain and immunoglobulin-like domains in the extracellular region. Specifically, the FLT3 receptor is composed of five distinct components ( Figure 1): an extracellular domain, a transmembrane region (TM), a juxtamembrane domain (JM), and a cytoplasmic tyrosine kinase domain (TKD), which are separated into two parts by a short region called the kinase insert (KI) [16]. The JM domain is composed of 3 topological parts: the JM-binding motif (JM-B), the switch motif (JM-S), and the linker/zipper peptide segment (JM-Z) [17]. JM-B makes contact with structural components implicated in the activation/inactivation cycle of the FLT3 cytoplasmic domain. JM-S is related to the activation and regulation of the FLT3 receptor enzyme. JM-Z can rotate around its attachment sites [ 17, 18]. Figure 1

Structure, localization, and cellular signaling of FLT3

(A) Western blots showing different patterns of wild-type and mutant FLT3 due to glycosylation. (B) FLT3-WT is expressed on the cell surface to activate the MAPK and AKT signaling pathways, while FLT3-ITD and FLT3-TKD are located mainly in the ER, where they activate the STAT5 signaling pathway. FLT3 contains five distinct components: an extracellular immunoglobulin-like (Ig-like) domain containing N-glycans, a transmembrane domain (TM), a juxtamembrane domain (JM), and a kinase insert (KI). The black bar (‒) indicates an internal tandem duplication (ITD) in FLT3-ITD or a tyrosine kinase domain (TKD) mutation in the FLT3-TKD mutant.

FLT3-ITD mutation in the JM domain causes constitutive activation of tyrosine kinases, leading to autophosphorylation of the receptors and subsequent activation of downstream signaling pathways such as signal transducers and activators of transcription 5 (STAT5), ultimately facilitating the progression of leukemia [ 16, 19, 20]. According to a recent risk stratification analysis of patients with AML, those harboring FLT3-ITD mutations exhibited a decreased likelihood of attaining complete remission and were at increased risk of disease relapse [21]. According to the updated ELN classification (2022), AML patients with FLT3-ITD mutations are classified into the intermediate-risk group [22]. In addition to the common ITD mutation, FLT3-TKD is found in 5% to 7% of AML patients. The predominant mutation observed is the substitution of the 835 aspartic acid residue [ 23, 24]. Several recent studies have demonstrated that posttranslational modifications associated with FLT3 mutations and their cellular localization can result in alterations in downstream signaling pathways [25]. FLT3-ITD and TKD mutations have been shown to induce receptor phosphorylation in the absence of ligands, thereby facilitating AML progression through the activation of STAT5 signaling [ 16, 19, 26].

FLT3 Glycosylation

Glycosylation, a commonly occurring posttranslational modification of proteins, has been associated with various physiological and pathological processes, including haematopoiesis and tumorigenesis [ 27‒ 29]. Numerous studies have demonstrated that glycosylation plays a vital role in protein folding, transport, location, dimer formation, and drug resistance [ 30‒ 34]. The N-glycosylation of FLT3 has garnered increasing attention.

Glycosylation status of FLT3-WT and its mutants

FLT3 is initially synthesized as a 110 kDa protein lacking glycan modifications and subsequently undergoes preliminary glycosylation in the endoplasmic reticulum (ER) to form a 130 kDa immature protein containing oligomannose. This immature protein is further processed in the Golgi apparatus to produce a 150 kDa complex-glycosylated protein, which can ultimately be transported to the cell surface ( Figure 1) [15]. The 150 kDa form is more prominent in the FLT3-WT cells than in the ITD and TKD mutant cells. In FLT3-ITD cells, the majority of FLT3 was found to be in the 130 kDa family, with a minor fraction in the mature family, whereas FLT3-TKD cells predominantly exhibit the 130 kDa family [ 15, 35]. The precise mechanism underlying the lower glycosylation levels in FLT3 mutants remains to be defined. Natarajan et al. [36] indicated that the interaction with the oncogenic serine/threonine kinase Pim-1 and subsequent serine phosphorylation by Pim-1 might contribute to the stabilization of the 130 kDa FLT3-ITD, preventing its further modification by complex types of glycans.

It has been reported that Galanthus nivalis lectin (GNA), a selective lectin with a mannose-rich structure [37], interacts specifically with the 130 kDa species of both FLT3-WT and FLT3-ITD [15], which suggests the presence of oligomannose types on FLT3-ITD. However, it was also reported that the 130 kDa form of FLT3-ITD or TKD, but not WT, contains core fucosylation confirmed by Aleuria aurantia lectin (AAL) [38], a lectin that preferentially recognizes core fucosylated N-glycans catalyzed by α-1,6-fucosyltransferase (FUT8) [ 39, 40]. Therefore, the glycosylation status of these cells differed between the FLT3-WT and FLT3-mutant groups. Although the mutants have been reported to mainly localize to the ER, they might be transported to the Golgi apparatus once and then reversely transported back to the ER through unknown mechanisms ( Figure 2). Figure 2

Proposed transport modes of FLT3-WT and the mutants

First, FLT3-WT and its mutants are processed in the ER. After primary After primary modification with oligomannose, they are transported to the Golgi apparatus for complex glycosylation (I). FLT3-WT is further processed in the Golgi for complete complex N-glycosylation (II) and is finally transported and expressed on the cell surface (III). On the other hand, the FLT3 mutants undergo light N-glycosylation, such as with hybrid N-glycan status, and are reversely transported back to the ER (II) through undefined mechanisms.

The expression of either WT or mutant FLT3 in Ba/F3 cells, which are interleukin-3 (IL-3)-dependent hematopoietic progenitor cells, significantly induced core fucosylation [38]. Interestingly, FUT8 deficiency ( FUT8-KO) induces cell growth in FLT3-WT Ba/F3 cells even without IL-3. Additionally, FUT8-KO significantly increases the phosphorylation of STAT5 and the activation of AKT and ERK without affecting the localization of FLT3-WT. A possible mechanism is that the deficiency of core fucosylation on FLT3 facilitates the dimerization of FLT3, leading to the aberrant activation of FLT3-WT-mediated signaling [38]. These findings indicate that core fucosylation is a critical factor in FLT3 signaling and provides a valuable avenue for treating AML. In contrast, ablation of FUT8 partially inhibits the proliferation of ITD and TKD cells, suggesting that glycan-mediated signaling is quite different between the WT and mutant strains.

Abnormal localization and cellular signaling of FLT3 caused by protein-protein interactions

Accumulating evidence suggests that the glycosylation level of FLT3 and dynamic changes in its subcellular localization significantly impact the activation of downstream signaling pathways. FLT3-WT is mainly localized on the cell surface and interacts with FL to be activated [41]. The combination of FLT3-WT with FL has been shown to activate several downstream signaling pathways, such as the PI3K/AKT and MAPK signaling pathways [ 42, 43]. In contrast, FLT3-ITD receptor proteins predominantly accumulate in the perinuclear region [ 44, 45]. Kouhei Yamawaki et al. [46] reported that the mutant FLT3-ITD protein is primarily localized in the ER and Golgi apparatus, with a minority fraction present at the plasma membrane. The differential location of FLT3-ITD mutations is related to differences in signal quality. FLT3-ITD localized at the cell surface strongly activates the MAPK and PI3K/AKT pathways. In contrast, FLT3-ITD localized at the ER aberrantly activates STAT5 but cannot upregulate the MAPK and PI3K/AKT pathways [ 47, 48]. Furthermore, plasma membrane-resident FLT3-ITD was also observed to activate K-Ras in AML cells [49]. Compared with FLT3-ITD, ER-anchored FLT3-TKD also weakly activates STAT5 ( Figure 1) [50]. Recent research indicated that the tyrosine kinase inhibitors quizartinib (AC220) and midostaurin (PKC412), both known to effectively inhibit FLT3 [ 51‒ 53], increase the plasma membrane distribution of FLT3-ITD [46]. Consistently, Reiter et al. [45] observed that treatment with AC220 resulted in a shift in the intracellular localization of FLT3-ITD and FLT3-TKD to a plasma membrane localization resembling that of FLT3-WT. Inhibition of the FLT3-ITD kinase by small molecules, inactivating point mutations, or co-expression with protein-tyrosine phosphatases enhances complex glycosylation and surface localization of the FLT3-ITD [15]. These findings serve as the foundation for the potential synergistic effect of combining a tyrosine kinase inhibitor with FLT3-directed immunotherapy in treating FLT3-ITD-positive AML patients.

The mechanisms underlying the changes in the subcellular localization of FLT3 resulted from activating mutations are receiving increasing attention. The first explanation is that the nucleophosmin-1 (NPM1) mutation (NPM1c) causes the mislocalization of FLT3-TKD and changes its signal transduction ability [54]. NPM1 mutation is another common gene aberration in AML patients [55]. NPM1c induces a shift in the subcellular localization of FLT3-TKD from the plasma membrane to the ER, facilitating the activation of STAT5 induced by FLT3-TKD. Moreover, aberrant STAT5 activation is observed in primary murine cells and AML patients harboring concurrent FLT3-TKD and NPM1c mutations.

Marcotegui et al. [56] recently revealed that the SET protein is involved in FLT3 trafficking. As a scaffold protein, SET co-localizes with FLT3 and facilitates the transport of nascent FLT3 to the cell membrane in FLT3-WT cells. SET nuclear retention decreased the amount of FLT3-WT on the membrane, underscoring the critical role of SET in FLT3 membrane trafficking. In contrast, the FLT3-ITD mutation impairs SET/FLT3 binding, contributing to its retention in the ER. When FLT3-WT cells were treated with tunicamycin, an inhibitor of protein glycosylation, the amount of FLT3 in the membrane significantly decreased, while the colocalization of SET/FLT3 remained unchanged. This finding implies that the SET/FLT3 interaction occurs before N-glycosylation. Furthermore, they suggested that the FLT3 inhibitor PKC412 facilitates the translocation of FLT3-ITD to the cytoplasmic membrane by enhancing the binding between FLT3 and SET.

Rai et al. [57] reported that clathrin assembly lymphoid myeloid leukemia protein (CALM) disrupts the intracellular localization of FLT3-ITD, consequently inhibiting its cellular signaling. CALM knockdown or chlorpromazine (which can reduce CALM protein expression) treatment reduced the co-localization of FLT3 ITD with the ER and inhibited the phosphorylation of STAT5. Additionally, studies have shown that chaperone proteins such as calreticulin, calnexin, and HSP90beta1 play direct roles in the retention of FLT3-ITD in the ER [34]. These results may provide insights into the mechanisms underlying the intracellular retention of FLT3 mutants.

Targeting drug therapy for FLT3 glycosylation

FLT3 inhibitors are widely utilized for the treatment of AML, significantly improve survival and have demonstrated notable enhancements in the survival rates and prognoses of individuals with AML [58]. However, the efficacy of FLT3-targeted tyrosine kinase inhibitors has been compromised by the development of adaptive and acquired resistance via various distinct mechanisms [59]. These limitations warrant the development of novel, targeted agents. The altered localization of FLT3 mutants caused by different glycosylation statuses affects their downstream signaling pathways, thus prompting increased interest in the investigation of glycosylation inhibitors as a potential therapeutic avenue for AML.

2-Deoxy-D-glucose (2-DG) is recognized as a sugar analogue that inhibits N-linked glycosylation. Due to its potent inhibition of the glycolytic pathway, the anticancer properties of 2-DG have been extensively investigated in solid tumors [ 60, 61]. According to previous reports [62], 2-DG inhibits cell viability and induces apoptotic cell death in FTL3-ITD-positive cells. Through N-linked glycosylation inhibition, 2-DG affects the cell surface expression and cellular signaling of FTL3-ITD. Moreover, the effect of 2-DG was also demonstrated in quizartinib-resistant FLT3-TKD cells. Since leukemia cells harboring FLT3-ITD mutations are more sensitive to 2-DG treatment than wild-type cells, 2-DG may serve as a promising therapeutic target for AML patients with mutated FLT3.

Statins were developed to lower cholesterol and triglyceride levels in the body. This is achieved through the inhibition of 3‑hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, a crucial enzyme that regulates the mevalonate pathway [63]. The mevalonate pathway is also involved in the biosynthesis of dolichol, which is related to the co-translational transfer of oligosaccharides to nascent polypeptides through N-linked glycosylation [64]. Previous research has shown that fluvastatin impairs the glycosylation of FLT3 and its transport to the cell surface of FLT3-ITD cells [59]. Fluvastatin has the potential to induce cytotoxic effects in mutant FLT3 leukemia cell lines through the disruption of signal transduction pathways, thus reducing tumor burden in vivo. Significantly, fluvastatin treatment effectively overcomes several resistance mechanisms, making it a potential therapeutic option for treating patients with FLT3-mutant AML.

Tunicamycin is a bacterial antibiotic that effectively inhibits the process of active sugar transfer to dolichol phosphate, which is a crucial step in the formation of N-glycosylated proteins in the ER [65]. As an inhibitor of N-linked oligosaccharide synthesis, tunicamycin has been demonstrated to induce cytotoxic effects and increase the sensitivity of various cancer cells to therapy [ 66, 67]. Tsitsipatis et al. [68] reported that inhibiting the maturation of the FLT3-ITD glycoprotein using low concentrations of tunicamycin had antiproliferative and proapoptotic effects on FLT3-ITD-expressing human and murine cell lines [68]. Low doses of tunicamycin significantly attenuate AKT and ERK activation in FLT3-ITD-positive cells. Tunicamycin demonstrated significant efficacy in reducing the viability of leukemia cell lines expressing FLT3-ITD and displayed synergistic effects with FLT3-ITD kinase inhibitors [68]. These findings suggest that a range of glycosylation inhibitors can decrease the glycosylation of FLT3 mutants, disrupting their plasma membrane expression and cellular signaling, providing novel insight for improving the therapeutic effect of AML treatment.

FLT3 Ubiquitination

Another essential post-translational modification of FLT3 is ubiquitination. Ubiquitination is a process in which ubiquitin forms a bond with a lysine residue at the target site of a protein, playing a crucial role in regulating almost all cellular metabolism [69]. This process is dynamic and reversible and is regulated by ubiquitin ligases and deubiquitin enzymes (DUBs) [70]. Ubiquitin is covalently conjugated to substrates through a complex three-step enzymatic process involving E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and various E3 ubiquitin ligases [ 71, 72]. Deubiquitination is the process of hydrolysing ubiquitin from a substrate or polyubiquitin chain and is regulated by a deubiquitinase [73]. Based on the diverse ubiquitination sites, many linkages exist in ubiquitin chains. Among them, K48- and K63-linked polyubiquitin chains are the most extensively researched and prevalent forms in cells [74]. According to the traditional understanding of K48-linked polyubiquitination, the proteasome can interact with a chain consisting of at least four ubiquitin moieties to target polyubiquitinated substrates for degradation [75]. The K63 chain is involved in DNA damage repair, receptor trafficking, kinase signaling pathways, and ribosomal biogenesis [76]. The ubiquitination of FLT3 is triggered by the activation of FLT3 through ligand binding and is mediated by multiple ubiquitin ligases, ultimately regulating the internalization and degradation of the receptor [ 77, 78]. FLT3 was found to be poly-ubiquitinated through both K48 and K63 linkages [16].

K48-linked ubiquitination of FLT3

As mentioned above, K48-linked chains are the most prevalent chain type and target proteins for proteasomal degradation. Cbl facilitates K48-linked polyubiquitination of autophosphorylated FLT3-ITD, and Cbl-mediated K48-linked ubiquitination is recognized by the proteasome, resulting in the degradation of FLT3 in proteasomes [ 79‒ 81]. The Cbl proteins are a highly conserved family of RING finger E3 ubiquitin ligases that regulate signaling via receptor and nonreceptor tyrosine kinases [82]. Members of the Cbl family are recognized as significant receptor tyrosine kinase ubiquitination regulators. Overexpression of loss-of-function Cbl mutants results in increased activation of FLT3 downstream signaling pathways, such as AKT and STAT5, further demonstrating its role in the negative regulation of FLT3 signaling [83].

Weisberg et al. [84] identified USP10, a K48-linked ubiquitin deubiquitinase, as an essential DUB required to stabilize FLT3. Pharmacological inhibition of USP10 results in the degradation of FLT3 and demonstrates efficacy in FLT3-ITD-positive AML models, including cell lines, primary patients, and mouse models.

K63-linked ubiquitination of FLT3

K63-linked chains are not involved in proteasomal degradation; however, they are crucial for the regulation of lysosomal functions and the internalization of membrane receptors [ 85, 86]. Both lysosomal and proteasomal degradation of FLT3 have been documented [ 79, 87]. K63-linked polyubiquitination of FLT3 has been reported to occur via neural precursor cell-expressed developmentally downregulated protein 4 (NEDD4) [79]. The deubiquitinase USP9X physically associates with FLT3-ITD, leading to the inhibition of its K63-linked polyubiquitination. The inhibition of USP9X by its inhibitor or USP9X-shRNA enhances K63-linked polyubiquitination of FLT3-ITD and induces apoptosis in FLT3-ITD-positive AML cells [88]. Downregulating USP9X can also reduce the expression levels of FLT3-ITD and its associated downstream signaling pathways, suggesting that USP9X represents a promising target for treating FLT3-ITD-positive AML patients.

Our recent study also demonstrated that K63-linked polyubiquitination plays a regulatory role in FLT3-ITD [35]. Using proximity labelling technology with TurboID, we found that BRCA1/BRCA2-containing complex subunit 36 (BRCC36), a specific K63-linked polyubiquitin deubiquitinase, was exclusively associated with ITD. TurboID is a novel proximity-dependent labelling technique that utilizes biotin and ATP to generate biotin-5'-AMP. This reactive intermediate can rapidly label lysine residues of proximal proteins. Biotinylated proteins are then digested, enriched, and identified. TurboID has higher activity, enabling higher temporal resolution and broader application in vivo [89]. Our results indicated the presence of K63-linked polyubiquitin on FLT3-ITD and showed that BRCC36 promotes its protein stability and activation by hydrolyzing K63-linked polyubiquitin chains. Moreover, it is worth noting that the BRCC36 inhibitor had synergistic effects with the FLT3 tyrosine kinase inhibitor for treating AML ( Figure 3). In general, attenuation of FLT3 stability by pharmacological modulation of ubiquitination has significant clinical advantages for patients with oncogenic FLT3-positive AML. Figure 3

Synergistic effects of BRCC36 inhibitors and FLT3 kinase inhibitors on FLT3-ITD-mediated signaling

BRCC36 hydrolyzes the K63-linked polyubiquitin chains of FLT3-ITD and promotes its protein stability. The BRCC36 inhibitor increases the number of K63-Ub chains on FLT3-ITD and induces its degradation. BRCC36 inhibitors and FLT3 kinase inhibitors have synergistic effects on suppressing FLT3-ITD activity.

Conclusion and Future Directions

Increasing research on FLT3 has significantly expanded our understanding of its biological function. FLT3-ITD mutation is a significant genetic alteration in AML and is a critical prognostic indicator for adverse outcomes in this hematologic malignancy. A distinct glycosylation status leads to the aberrant localization of mutant FLT3 in cells, triggering the aberrant signaling pathway. FLT3-WT is thought to be fully N-glycosylated and is then expressed on the cell surface to activate the AKT and MAPK signaling pathways. On the other hand, FLT3-ITD displays reduced glycosylation and mainly localizes to the ER, leading to efficient activation of STAT5. As described above, many factors contribute to the aberrant PTM and localization of FLT3 mutants.

To date, most of our current understanding of the downstream signaling pathway of FLT3 has been derived from studies utilizing transfected cell lines or cells from individuals with AML. Transgenic mice lacking specific signal transduction molecules or mice expressing FLT3 mutants have not yet been extensively used to study FLT3 function. Therefore, related work needs to be performed.

Given the significant role of FLT3 in AML, further elucidation of the underlying mechanisms is needed. Improving our understanding of signaling in individual AML patients is necessary. The different responses of patients to current selective kinase inhibitors may be attributed to variations in the microenvironment and epigenetic factors among the individual patients. In addition, considering the propensity of leukemia to develop resistance to FLT3 inhibitors, we need to gain a deeper understanding of the mechanism by which FLT3 signals in AML cells. This knowledge enables the identification of novel target molecules for drug development, potentially leading to the development of novel therapies.

COMPETING INTERESTS

The authors declare that they have no conflict of interest.
==== Refs
1 Yang Q Tian H Guo Z Ma Z Wang G The role of noncoding RNAs in the tumor microenvironment of hepatocellular carcinoma Acta Biochim Biophys Sin 2023 55 1697 1706 10.3724/abbs.2023231 37867435
2 Wachter F Pikman Y Pathophysiology of acute myeloid leukemia Acta Haematol 2024 147 229 246 10.1159/000536152 38228114
3 Sasaki K Ravandi F Kadia TM DiNardo CD Short NJ Borthakur G Jabbour E et al. De novo acute myeloid leukemia: a population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 Cancer 2021 127 2049 2061 10.1002/cncr.33458 33818756
4 Bain BJ Béné MC Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia Acta Haematol 2019 141 232 244 10.1159/000496097 30965338
5 Medeiros BC Chan SM Daver NG Jonas BA Pollyea DA Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia Am J Hematol 2019 94 803 811 10.1002/ajh.25484 30945331
6 Papaemmanuil E Gerstung M Bullinger L Gaidzik VI Paschka P Roberts ND Potter NE et al. Genomic classification and prognosis in acute myeloid leukemia N Engl J Med 2016 374 2209 2221 10.1056/NEJMoa1516192 27276561
7 Safaei A, Monabati A, Mokhtari M, Safavi M, Solhjoo F. Evaluation of the CD123 expression and FLT3 gene mutations in patients with acute myeloid leukemia. Iran J Pathol 2018, 13: 438–446
8 Stirewalt DL Kopecky KJ Meshinchi S Engel JH Pogosova-Agadjanyan EL Linsley J Slovak ML et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia Blood 2006 107 3724 3726 10.1182/blood-2005-08-3453 16368883
9 D. Kottaridis P Gale RE Linch DC Flt3 mutations and leukaemia Br J Haematol 2003 122 523 538 10.1046/j.1365-2141.2003.04500.x 12899708
10 Thiede C Koch S Creutzig E Steudel C Illmer T Schaich M Ehninger G Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 2006 107 4011 4020 10.1182/blood-2005-08-3167 16455956
11 Bacher U Haferlach C Kern W Haferlach T Schnittger S Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients Blood 2008 111 2527 2537 10.1182/blood-2007-05-091215 17965322
12 Ozeki K Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia Blood 2004 103 1901 1908 10.1182/blood-2003-06-1845 14604973
13 Venne AS Kollipara L Zahedi RP The next level of complexity: Crosstalk of posttranslational modifications Proteomics 2014 14 513 524 10.1002/pmic.201300344 24339426
14 Huang KY Su MG Kao HJ Hsieh YC Jhong JH Cheng KH Huang HD et al. dbPTM 2016: 10-year anniversary of a resource for post-translational modification of proteins Nucleic Acids Res 2016 44 D435 D446 10.1093/nar/gkv1240 26578568
15 Schmidt-Arras DE Böhmer A Markova B Choudhary C Serve H Böhmer FD Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases Mol Cell Biol 2005 25 3690 3703 10.1128/MCB.25.9.3690-3703.2005 15831474
16 Kazi JU Rönnstrand L FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications Physiol Rev 2019 99 1433 1466 10.1152/physrev.00029.2018 31066629
17 Griffith J Black J Faerman C Swenson L Wynn M Lu F Lippke J et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol Cell 2004 13 169 178 10.1016/S1097-2765(03)00505-7 14759363
18 Hu X Chen F Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia Hematology 2019 24 651 660 10.1080/16078454.2019.1666219 31533545
19 Cai J Huang H Hu X Lang W Fu W Xu L Qiu Z et al. Homoharringtonine synergized with gilteritinib results in the downregulation of myeloid cell leukemia-1 by upregulating UBE2L6 in FLT3-ITD-Mutant acute myeloid (leukemia) cell lines J Oncol 2021 2021 3766428 10.1155/2021/3766428 34594375
20 Schmalbrock LK Dolnik A Cocciardi S Sträng E Theis F Jahn N Panina E et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin Blood 2021 137 3093 3104 10.1182/blood.2020007626 33598693
21 Tazi Y Arango-Ossa JE Zhou Y Bernard E Thomas I Gilkes A Freeman S et al. Unified classification and risk-stratification in acute myeloid leukemia Nat Commun 2022 13 4622 10.1038/s41467-022-32103-8 35941135
22 Döhner H Wei AH Appelbaum FR Craddock C DiNardo CD Dombret H Ebert BL et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Blood 2022 140 1345 1377 10.1182/blood.2022016867 35797463
23 Yamamoto Y Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies Blood 2001 97 2434 2439 10.1182/blood.V97.8.2434 11290608
24 Thiede C Steudel C Mohr B Schaich M Schäkel U Platzbecker U Wermke M et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 2002 99 4326 4335 10.1182/blood.V99.12.4326 12036858
25 Chen Y Zou Z Găman MA Xu L Li J NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia Cell Death Discov 2023 9 208 10.1038/s41420-023-01528-5 37391442
26 Grundler R Thiede C Miething C Steudel C Peschel C Duyster J Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor Blood 2003 102 646 651 10.1182/blood-2002-11-3441 12663439
27 Pang X Li H Guan F Li X Multiple roles of glycans in hematological malignancies Front Oncol 2018 8 364 10.3389/fonc.2018.00364 30237983
28 Reily C Stewart TJ Renfrow MB Novak J Glycosylation in health and disease Nat Rev Nephrol 2019 15 346 366 10.1038/s41581-019-0129-4 30858582
29 Läubli H Borsig L Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis Front Immunol 2019 10 2120 10.3389/fimmu.2019.02120 31552050
30 Helenius A Aebi M Intracellular functions of N-Linked glycans Science 2001 291 2364 2369 10.1126/science.291.5512.2364 11269317
31 Czuba LC Hillgren KM Swaan PW Post-translational modifications of transporters Pharmacol Ther 2018 192 88 99 10.1016/j.pharmthera.2018.06.013 29966598
32 Patwardhan A Cheng N Trejo JA Schulte G Post-translational modifications of G protein-coupled receptors control cellular signaling dynamics in space and time Pharmacol Rev 2021 73 120 151 10.1124/pharmrev.120.000082 33268549
33 Fonseca LM Silva VA Freire-de-Lima L Previato JO Mendonça-Previato L Capella MAM Glycosylation in cancer: interplay between multidrug resistance and epithelial-to-mesenchymal transition? Front Oncol 2016 6 10.3389/fonc.2016.00158
34 Fleischmann M Fischer M Schnetzke U Fortner C Kirkpatrick J Heidel FH Hochhaus A et al. Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance Cells 2021 10 2992 10.3390/cells10112992 34831215
35 Liu J Isaji T Komatsu S Sun Y Xu X Fukuda T Fujimura T et al. BRCC36 associates withFLT3‐ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia Cancer Sci 2024 115 1196 1208 10.1111/cas.16090 38288901
36 Natarajan K Xie Y Burcu M Linn DE Qiu Y Baer MR Bunting KD Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication PLoS One 2013 8 e74653 10.1371/journal.pone.0074653 24040307
37 Shibuya N Goldstein IJ Van Damme EJ Peumans WJ Binding properties of a mannose-specific lectin from the snowdrop ( Galanthus nivalis) bulb J Biol Chem 1988 263 728 734 10.1016/S0021-9258(19)35413-4 3335522
38 Duan C Fukuda T Isaji T Qi F Yang J Wang Y Takahashi S et al. Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system FASEB J 2020 34 3239 3252 10.1096/fj.201902313RR 31908039
39 Gu W Fukuda T Isaji T Hashimoto H Wang Y Gu J α1,6‐Fucosylation regulates neurite formation via the activin/phospho‐Smad2 pathway in PC12 cells: the implicated dual effects of Fut8 for TGF‐β/activin‐mediated signaling FASEB J 2013 27 3947 3958 10.1096/fj.12-225805 23796784
40 Lu X Zhang D Shoji H Duan C Zhang G Isaji T Wang Y et al. Deficiency of α1,6-fucosyltransferase promotes neuroinflammation by increasing the sensitivity of glial cells to inflammatory mediators Biochim Biophys Acta Gen Subj 2019 1863 598 608 10.1016/j.bbagen.2018.12.008 30572004
41 Tsapogas P Mooney C Brown G Rolink A The cytokine Flt3-Ligand in normal and malignant hematopoiesis Int J Mol Sci 2017 18 1115 10.3390/ijms18061115 28538663
42 Masson K Liu T Khan R Sun J Rönnstrand L A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival Br J Haematol 2009 146 193 202 10.1111/j.1365-2141.2009.07725.x 19438505
43 Marchetto S Fournier E Beslu N Aurran-Schleinitz T Dubreuil P Borg JP Birnbaum D et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor Leukemia 1999 13 1374 1382 10.1038/sj.leu.2401527 10482988
44 Koch S Jacobi A Ryser M Ehninger G Thiede C Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis Cells Tissues Organs 2008 188 225 235 10.1159/000118788 18303245
45 Reiter K Polzer H Krupka C Maiser A Vick B Rothenberg-Thurley M Metzeler KH et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia Leukemia 2018 32 313 322 10.1038/leu.2017.257 28895560
46 Yamawaki K Shiina I Murata T Tateyama S Maekawa Y Niwa M Shimonaka M et al. FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells Sci Rep 2021 11 22678 10.1038/s41598-021-02221-2 34811450
47 Schmidt-Arras D Böhmer SA Koch S Müller JP Blei L Cornils H Bauer R et al. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality Blood 2009 113 3568 3576 10.1182/blood-2007-10-121426 19204327
48 Choudhary C Olsen JV Brandts C Cox J Reddy PNG Böhmer FD Gerke V et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes Mol Cell 2009 36 326 339 10.1016/j.molcel.2009.09.019 19854140
49 Köthe S Müller JP Böhmer SA Tschongov T Fricke M Koch S Thiede C et al. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals via K-Ras at the plasma membrane of acute myeloid leukemia cells J Cell Sci 2013 126 4746 4755 10.1242/jcs.131789 23943874
50 Choudhary C Schwäble J Brandts C Tickenbrock L Sargin B Kindler T Fischer T et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations Blood 2005 106 265 273 10.1182/blood-2004-07-2942 15769897
51 Zarrinkar PP Gunawardane RN Cramer MD Gardner MF Brigham D Belli B Karaman MW et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 2009 114 2984 2992 10.1182/blood-2009-05-222034 19654408
52 Gallogly MM Lazarus HM Cooper BW Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis Ther Adv Hematol 2017 8 245 261 10.1177/2040620717721459 29051803
53 Pratz KW Sato T Murphy KM Stine A Rajkhowa T Levis M FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML Blood 2010 115 1425 1432 10.1182/blood-2009-09-242859 20007803
54 Rudorf A Müller TA Klingeberg C Kreutmair S Poggio T Gorantla SP Rückert T et al. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia Blood 2019 134 383 388 10.1182/blood.2018883140 31186273
55 Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368: 2059–2074
56 Marcotegui N Romero-Murillo S Marco-Sanz J Peris I Berrozpe BS Vicente C Odero MD et al. Set protein is involved in FLT3 membrane trafficking Cancers 2023 15 2233 10.3390/cancers15082233 37190162
57 Rai S Tanaka H Suzuki M Espinoza JL Kumode T Tanimura A Yokota T et al. Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V Nat Commun 2020 11 4147 10.1038/s41467-020-17666-8 32811837
58 Jiang K Li X Wang C Hu X Wang P Tong L Tu Y et al. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia Leukemia 2023 37 539 549 10.1038/s41375-022-01795-8 36526736
59 Williams AB Li L Nguyen B Brown P Levis M Small D Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia Blood 2012 120 3069 3079 10.1182/blood-2012-01-403493 22927251
60 Pajak B Siwiak E Sołtyka M Priebe A Zieliński R Fokt I Ziemniak M et al. 2-Deoxy-D-Glucose and its analogs: from diagnostic to therapeutic agents Int J Mol Sci 2019 21 234 10.3390/ijms21010234 31905745
61 Pelicano H Martin DS Xu RH Huang P Glycolysis inhibition for anticancer treatment Oncogene 2006 25 4633 4646 10.1038/sj.onc.1209597 16892078
62 Larrue C Saland E Vergez F Serhan N Delabesse E Mansat-De Mas V Hospital MA et al. Antileukemic activity of 2-deoxy-D-glucose through Inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations Mol Cancer Ther 2015 14 2364 2373 10.1158/1535-7163.MCT-15-0163 26206337
63 Corsini A Pharmacology of competitive inhibitors of HMg-CoA reductase Pharmacol Res 1995 31 9 27 10.1016/1043-6618(95)80042-5 7784310
64 Mo H Elson CE Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention Exp Biol Med (Maywood) 2004 229 567 585 10.1177/153537020422900701 15229351
65 Keenan RW Hamill RL Occolowitz JL Elbein AD Biological activities of isolated tunicamycin and streptovirudin fractions Biochemistry 1981 20 2968 2973 10.1021/bi00513a039 6454439
66 Helenius A Aebi M Roles of N-linked glycans in the endoplasmic reticulum Annu Rev Biochem 2004 73 1019 1049 10.1146/annurev.biochem.73.011303.073752 15189166
67 Ahmmed B Khan MN Nisar MA Kampo S Zheng Q Li Y Yan Q Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway Int J Oncol 2019 54 431 442 10.3892/ijo.2018.4650 30483742
68 Tsitsipatis D Jayavelu AK Müller JP Bauer R Schmidt-Arras D Mahboobi S Schnöder TM et al. Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation Oncotarget 2017 8 26613 26624 10.18632/oncotarget.15772 28460451
69 Swatek KN Komander D Ubiquitin modifications Cell Res 2016 26 399 422 10.1038/cr.2016.39 27012465
70 Zong Z Zhang Z Wu L Zhang L Zhou F The functional deubiquitinating enzymes in control of innate antiviral immunity Adv Sci 2021 8 2002484 10.1002/advs.202002484
71 Li W Ye Y Polyubiquitin chains: Functions, structures, and mechanisms Cell Mol Life Sci 2008 65 2397 2406 10.1007/s00018-008-8090-6 18438605
72 Pickart CM Mechanisms underlying ubiquitination Annu Rev Biochem 2001 70 503 533 10.1146/annurev.biochem.70.1.503 11395416
73 Eletr ZM Wilkinson KD Regulation of proteolysis by human deubiquitinating enzymes Biochim Biophys Acta 2014 1843 114 128 10.1016/j.bbamcr.2013.06.027 23845989
74 Ohtake F Saeki Y Ishido S Kanno J Tanaka K The K48-K63 branched ubiquitin chain regulates NF-κB signaling Mol Cell 2016 64 251 266 10.1016/j.molcel.2016.09.014 27746020
75 Thrower JS Recognition of the polyubiquitin proteolytic signal EMBO J 2000 19 94 102 10.1093/emboj/19.1.94 10619848
76 Cao L Liu X Zheng B Xing C Liu J Role of K63-linked ubiquitination in cancer Cell Death Discov 2022 8 410 10.1038/s41420-022-01204-0 36202787
77 Buchwald M Pietschmann K Müller JP Böhmer FD Heinzel T Krämer OH Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation Leukemia 2010 24 1412 1421 10.1038/leu.2010.114 20508617
78 Kazi JU Sun J Phung B Zadjali F Flores-Morales A Rönnstrand L Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3 J Biol Chem 2012 287 36509 36517 10.1074/jbc.M112.376111 22952242
79 Oshikawa G Nagao T Wu N Kurosu T Miura O c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway J Biol Chem 2011 286 30263 30273 10.1074/jbc.M111.232348 21768087
80 Jung T Catalgol B Grune T The proteasomal system Mol Aspects Med 2009 30 191 296 10.1016/j.mam.2009.04.001 19371762
81 Zhimin L Tony H Degradation of activated protein kinases by ubiquitination Annu Rev Biochem 2009 78 435 475 10.1146/annurev.biochem.013008.092711 19489726
82 Swaminathan G Tsygankov AY The Cbl family proteins: ring leaders in regulation of cell signaling J Cell Physiol 2006 209 21 43 10.1002/jcp.20694 16741904
83 Reindl C Quentmeier H Petropoulos K Greif PA Benthaus T Argiropoulos B Mellert G et al. CBL Exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes Clin Canc Res 2009 15 2238 2247 10.1158/1078-0432.CCR-08-1325
84 Weisberg EL Schauer NJ Yang J Lamberto I Doherty L Bhatt S Nonami A et al. Inhibition of USP10 induces degradation of oncogenic FLT3 Nat Chem Biol 2017 13 1207 1215 10.1038/nchembio.2486 28967922
85 Zhao L Zhao J Zhong K Tong A Jia D Targeted protein degradation: Mechanisms, strategies and application Signal Transduct Target Ther 2022 7 113 10.1038/s41392-022-00966-4 35379777
86 Duncan LM Piper S Dodd RB Saville MK Sanderson CM Luzio JP Lehner PJ Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules EMBO J 2006 25 1635 1645 10.1038/sj.emboj.7601056 16601694
87 Kazi JU Rönnstrand L Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling Mol Oncol 2013 7 693 703 10.1016/j.molonc.2013.02.020 23548639
88 Akiyama H Umezawa Y Ishida S Okada K Nogami A Miura O Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress Cancer Lett 2019 453 84 94 10.1016/j.canlet.2019.03.046 30946869
89 Cho KF Branon TC Udeshi ND Myers SA Carr SA Ting AY Proximity labeling in mammalian cells with TurboID and split-TurboID Nat Protoc 2020 15 3971 3999 10.1038/s41596-020-0399-0 33139955
